- Home
- AKRO vs ULCC Comparison
AKRO vs ULCC Comparison
Compare AKRO & ULCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- ULCC
- Stock Information
- Founded
- AKRO 2017
- ULCC 1994
- Country
- AKRO United States
- ULCC United States
- Employees
- AKRO N/A
- ULCC N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- ULCC Air Freight/Delivery Services
- Sector
- AKRO Health Care
- ULCC Consumer Discretionary
- Exchange
- AKRO Nasdaq
- ULCC Nasdaq
- Market Cap
- AKRO 1.8B
- ULCC 1.9B
- IPO Year
- AKRO 2019
- ULCC 2021
- Fundamental
- Price
- AKRO $51.84
- ULCC $7.94
- Analyst Decision
- AKRO Strong Buy
- ULCC Hold
- Analyst Count
- AKRO 9
- ULCC 11
- Target Price
- AKRO $75.86
- ULCC $7.41
- AVG Volume (30 Days)
- AKRO 2.2M
- ULCC 3.2M
- Earning Date
- AKRO 03-03-2025
- ULCC 02-07-2025
- Dividend Yield
- AKRO N/A
- ULCC N/A
- EPS Growth
- AKRO N/A
- ULCC N/A
- EPS
- AKRO N/A
- ULCC 0.37
- Revenue
- AKRO N/A
- ULCC $3,775,000,000.00
- Revenue This Year
- AKRO N/A
- ULCC $17.35
- Revenue Next Year
- AKRO N/A
- ULCC $12.48
- P/E Ratio
- AKRO N/A
- ULCC $21.55
- Revenue Growth
- AKRO N/A
- ULCC 5.18
- 52 Week Low
- AKRO $17.86
- ULCC $2.79
- 52 Week High
- AKRO $58.40
- ULCC $10.26
- Technical
- Relative Strength Index (RSI)
- AKRO 65.39
- ULCC 44.78
- Support Level
- AKRO $48.70
- ULCC $8.36
- Resistance Level
- AKRO $51.40
- ULCC $9.44
- Average True Range (ATR)
- AKRO 2.29
- ULCC 0.64
- MACD
- AKRO -0.90
- ULCC -0.12
- Stochastic Oscillator
- AKRO 35.50
- ULCC 7.20
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers.